Dr Reddy’s Laboratories (RDY) has released an update.
Dr. Reddy’s Laboratories has invested $620 million into its wholly-owned subsidiary, DRL SA, Switzerland, for the acquisition of Nicotinell and related brands. This strategic move, which is a related party transaction done at arm’s length, aims to bolster the company’s pharmaceutical portfolio and strengthen its market position. The investment involved the allotment of 6.2 million non-convertible preference shares to the parent company.
For further insights into RDY stock, check out TipRanks’ Stock Analysis page.
